Somo la 1Uundaji wa arrhythmia ya atria na thromboembolism katika atrial fibrillation ya muda mrefu: urekebishaji wa atria, kusimama, na hatari ya kiharusiInaelezea jinsi ugonjwa wa atrial fibrillation wa muda mrefu unavyobadilisha muundo na utendaji wa atria, kukuza kusimama kwa damu, na kuongeza hatari ya thromboembolism, ikichanganya biolojia ya urekebishaji na utabiri wa kiharusi kliniki, uchunguzi wa picha, na mikakati ya kuzuia damu.
Electrical and structural atrial remodelingLoss of atrial kick and hemodynamic impactLeft atrial appendage stasis and clotCHA₂DS₂-VASc and bleeding risk scoresImaging of atrial thrombus and flowPathophysiology of cardioembolic strokeSomo la 2Pathofiziolojia ya ischemia katika ST-elevation myocardial infarction (STEMI): kupasuka kwa plaque, thrombosis, infarction ya transmural na anatomia maalum ya ukuta wa chiniInashughulikia mfululizo kutoka kupasuka kwa plaque hadi kufungwa kwa thrombosis na infarction ya transmural katika STEMI, ikisisitiza anatomia ya coronary, udhaifu wa ukuta wa chini, ushiriki wa ventricular ya kulia, na maana kwa dalili, ECG, na tiba.
Plaque rupture and thrombosis cascadeComplete occlusion and wavefront necrosisTransmural injury and ST-elevation patternsInferior wall blood supply and variantsRight ventricular infarction physiologyReperfusion injury and salvageable myocardiumSomo la 3Mwingiliano wa magonjwa ya kawaida pamoja (shinikizo la damu, kisukari, CKD, kiharusi kilichopita, sigara, hyperlipidemia) na pathofiziolojia ya moyoInachanganya jinsi shinikizo la damu, kisukari, CKD, kiharusi kilichopita, sigara, na hyperlipidemia zinavyoingiliana na muundo wa moyo, mishipa, na hemostasis, kuharakisha atherosclerosis, urekebishaji, arrhythmia, na maendeleo ya kushindwa kwa moyo.
Hypertension and pressure overload LVHDiabetes, microvascular disease, and HFCKD, uremic toxins, and volume overloadHyperlipidemia and atherosclerotic burdenSmoking, endothelial injury, and thrombosisPrior stroke and cardio-cerebral interplaySomo la 4Mapungufu ya miundo ya pathofiziolojia na tafsiri kwa wagonjwa wenye multimorbidity na umri mkubwaInajadili kwa nini miundo ya pathofiziolojia ya kawaida inaweza kushindwa katika watu wazima wakubwa na wagonjwa wa multimorbidity, ikiangazia akiba iliyobadilishwa, polypharmacy, udhaifu, na hatari zinazoshindana zinazofanya utambuzi, utabiri wa hatari, na chaguo za matibabu ziwe ngumu.
Physiologic aging and reduced reserveAtypical presentations in older patientsMultimorbidity and competing mechanismsPolypharmacy and altered drug responseRisk scores in heterogeneous populationsIndividualizing goals and shared decisionsSomo la 5Mifumo ya pharmacologic: ACEi/ARB/ARNI, beta blockers, MRAs, SGLT2 inhibitors, antiplatelet na wakala wa anticoagulant, reperfusion therapies na athari zao za fiziolojiaInapitia mifumo ya madawa ya madawa makubwa ya moyo, ikichanganya malengo ya receptor na njia za signaling na athari za hemodinamiki, neurohormonal, na antithrombotic, na kuelezea jinsi hizi zinavyotafsiriwa kuwa faraja ya dalili na faida za matokeo.
RAAS blockade with ACEi, ARB, and ARNIBeta-blockers and sympathetic modulationMRAs and aldosterone-driven remodelingSGLT2 inhibitors and cardiorenal effectsAntiplatelet pathways and platelet inhibitionAnticoagulants and coagulation cascade targetsSomo la 6Matokeo ya hemodinamiki ya LVEF iliyopungua: preload, afterload, contractility, na congestion inayoelezea dyspnea, orthopnea, JVP, crackles, edemaInaelezea jinsi kupungua kwa ejection fraction ya ventricular ya kushoto kunavyobadilisha preload, afterload, na contractility, kutoa congestion na output ya chini, na kuunganisha mabadiliko haya na ishara za kitanda kama dyspnea, orthopnea, kupanda kwa JVP, crackles, na edema.
Frank–Starling curve in systolic failureAfterload, arterial tone, and LV performanceNeurohormonal responses to low outputPulmonary venous hypertension and dyspneaSystemic venous congestion and edemaJVP, hepatojugular reflux, and exam cluesSomo la 7Msingi wa fiziolojia kwa matokeo ya vipimo vya utambuzi: mabadiliko ya ECG (LVH, inferior ST-elevations, AF), matokeo ya echo katika HFrEF na abnormalities za mwendo wa ukuta, biomarkers (troponin, BNP/NT-proBNP)Inachunguza jinsi fiziolojia ya moyo inavyotengeneza mifumo ya ECG, echocardiographic, na biomarker, kuruhusu wanafunzi kutafsiri LVH, ischemia, atrial fibrillation, na matokeo ya kushindwa kwa moyo kwa njia ya kinadharia, yenye manufaa kliniki.
Voltage criteria and repolarization in LVHInferior ST-elevation and coronary anatomyAF mechanisms and ECG irregularityEcho features of HFrEF and wall motionTroponin kinetics and myocardial necrosisBNP/NT-proBNP and wall stress physiologySomo la 8Urekebishaji wa moyo na mifumo ya kushindwa kwa systolic inayoongoza kwa kushindwa kwa moyo na ejection fraction iliyopungua (HFrEF)Inaelezea michakato ya kimolekuli, seli, na muundo inayoendesha urekebishaji wa moyo na kushindwa kwa systolic katika HFrEF, pamoja na uanzishaji wa neurohormonal, jeraha la myocyte, fibrosis, na upanuzi wa chumba, na jinsi mabadiliko haya yanavyozidisha utendaji wa pampu.
Myocyte loss, apoptosis, and necrosisHypertrophy, dilation, and geometry changeFibrosis, stiffness, and conduction delayNeurohormonal drivers of remodelingMitral regurgitation from LV dilationReverse remodeling with guideline therapy